Reimbursed Care Access in Svalbard and Jan Mayen

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Possession, sale, cultivation and preparations containing psilocybin are prohibited under Norwegian regulations and enforcement practice. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. MDMA may be accessed only through formal clinical trials or authorised research programs; private or off‑label clinical use is not permitted. #

Esketamine (marketed as SPRAVATO®) is authorised in the European/EEA regulatory framework for treatment‑resistant major depressive disorder and related emergency indications; this authorisation applies to Norway as an EEA country. The product label and European Commission authorisation are the regulatory basis for clinical use. #

Public financing and routine reimbursement of Spravato in Norway have been limited: Norwegian health‑technology assessments and payer decisions have not broadly adopted on‑label public funding for Spravato, meaning access for most patients is constrained by local hospital/practice decisions and out‑of‑pocket cost unless specific local funding arrangements are established. Several HTA and market‑access discussions in Norway cite cost‑effectiveness concerns and have left Spravato without wide public financing despite its marketing authorisation. #

Clinical / practical notes: where used on‑label, esketamine must be administered under supervised conditions with vital‑sign monitoring per product guidance; reimbursement status and delivery pathways should be confirmed with the treating institution and the Norwegian Medicines Agency (Statens legemiddelverk) or local hospital pharmacy services.

Ketamine (racemic ketamine) is an authorised medicinal product in Norway for anaesthesia and other licensed indications and has been used off‑label in psychiatric care. In recent national policy decisions Norway has moved to formally permit and reimburse off‑label intravenous ketamine administered within the public specialist mental health services for treatment‑resistant depression (TRD), subject to clinical protocols, data collection and oversight. This implementation is notable because it establishes national public reimbursement for an off‑label use when delivered within specified hospital outpatient/inpatient specialist services. # #

Regulatory and payer details: the Norwegian decision path included health‑technology assessment input and regional pilot/implementation experience (notably Østfold Hospital), and the reimbursement arrangement requires that ketamine for TRD be delivered within public hospitals or outpatient specialist mental health services (DPS) with standardized protocols, patient registries and informed consent for off‑label treatment. Private clinic delivery outside these public specialist pathways has been excluded from the initial national reimbursement decision. The decision is being treated as a time‑limited policy to collect longer‑term data and will be re‑evaluated at a defined future review date. # #

Clinical implications and access: clinicians must follow specialist mental‑health service pathways; treatment is typically paired with psychotherapy as required by the implementation model; patients should be informed it is an off‑label indication even when reimbursed by the public system. For up‑to‑date local operational rules and referral pathways, contact the regional health authority or the treating hospital's psychiatry department.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Preparations that contain DMT (including ayahuasca preparations) are treated as narcotic preparations under Norwegian law, and possession/use outside authorised research is prohibited. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Enforcement treats synthetic and extractive forms as prohibited, and there is no regulated medical pathway. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no authorised medical or reimbursement pathway for ibogaine in Norway. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Because ayahuasca preparations contain DMT, they are treated as narcotic preparations and are prohibited outside approved research; ritual or religious exception pathways are not recognised as lawful means of possession or distribution in Norway. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Peyote, synthetic mescaline and mescaline‑containing materials are prohibited except within authorised scientific trials. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. All substituted phenethylamines of the 2‑C family are controlled under Norwegian drug legislation and enforcement. #